LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

REVOLUTION Medicines Inc

Geschlossen

BrancheGesundheitswesen

39.73 2.63

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.69

Max

39.85

Schlüsselkennzahlen

By Trading Economics

Einkommen

-19M

-213M

EPS

-1.13

Gewinnspanne

-74.379

Angestellte

616

EBITDA

-24M

-237M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+80.64% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-147M

7.4B

Vorheriger Eröffnungskurs

37.1

Vorheriger Schlusskurs

39.73

Nachrichtenstimmung

By Acuity

9%

91%

12 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

REVOLUTION Medicines Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Mai 2025, 23:48 UTC

Heiße Aktien

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22. Mai 2025, 23:07 UTC

Top News

Fortescue Energy CEO to Resign in Executive Overhaul

22. Mai 2025, 23:03 UTC

Wichtige Markttreiber

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22. Mai 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22. Mai 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22. Mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22. Mai 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22. Mai 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22. Mai 2025, 23:12 UTC

Top News

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22. Mai 2025, 21:54 UTC

Top News

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22. Mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Mai 2025, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22. Mai 2025, 20:39 UTC

Ergebnisse

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22. Mai 2025, 20:36 UTC

Top News

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22. Mai 2025, 20:36 UTC

Top News
Ergebnisse

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22. Mai 2025, 20:32 UTC

Top News
Ergebnisse

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. Mai 2025, 20:27 UTC

Top News

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22. Mai 2025, 20:20 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. Mai 2025, 20:17 UTC

Top News

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22. Mai 2025, 20:16 UTC

Ergebnisse

Intchains Group 1Q Rev $18.2M >ICG

22. Mai 2025, 20:15 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. Mai 2025, 20:08 UTC

Top News
Ergebnisse

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. Mai 2025, 20:05 UTC

Top News

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22. Mai 2025, 20:04 UTC

Ergebnisse

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22. Mai 2025, 20:04 UTC

Ergebnisse

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Net $68M >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q EPS 25c >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Adj EPS $2.23 >WDAY

Peer-Vergleich

Kursveränderung

REVOLUTION Medicines Inc Prognose

Kursziel

By TipRanks

80.64% Vorteil

12-Monats-Prognose

Durchschnitt 70.09 USD  80.64%

Hoch 80 USD

Tief 57 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REVOLUTION Medicines Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

12

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

40.67 / 41.96Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

12 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.